重大好新闻： ECYT 重新要回全世界ovarian cancer drug开发权# Stock
L*k
1 楼
CEO 5分钟前重申， 对此药信心百倍！
明天就是翻倍的节奏
Endocyte Regains Worldwide Rights to Vintafolide
GlobeNewswire
Endocyte, Inc. 1 hour ago
WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (
ECYT) today announced that it has regained the worldwide rights to
vintafolide in all indications from Merck, known as MSD outside the United
States and Canada. Following a comprehensive portfolio assessment, Merck,
through a subsidiary, has decided that it will no longer pursue development
of vintafolide.
Endocyte will evaluate vintafolide for future development opportunities
pending final results from the Phase 2b TARGET trial in patients with non-
small cell lung cancer (NSCLC). The companies announced in March that the
TARGET trial met its primary progression-free-survival (PFS) endpoint and
overall response rates and early overall survival (OS) trends were positive.
Neither company has received updated overall survival data since that
announcement.
"We look forward to presenting detailed data from the ongoing Phase 2b
TARGET trial at an upcoming scientific conference later this year, which
will inform the path forward for vintafolide," said Ron Ellis, Endocyte's
president and chief executive officer. "We remain confident in our SMDC
platform and are in a strong financial position to continue to advance two
proprietary SMDCs with the more potent tubulysin warhead. Tubulysin has
demonstrated curative activity in preclinical models that were resistant to
paclitaxel, cisplatin and vintafolide. These two SMDCs are currently in
Phase 1 development: EC1456, targeting the folate receptor, and EC1169,
targeting prostate-specific membrane antigen (PSMA)."
明天就是翻倍的节奏
Endocyte Regains Worldwide Rights to Vintafolide
GlobeNewswire
Endocyte, Inc. 1 hour ago
WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (
ECYT) today announced that it has regained the worldwide rights to
vintafolide in all indications from Merck, known as MSD outside the United
States and Canada. Following a comprehensive portfolio assessment, Merck,
through a subsidiary, has decided that it will no longer pursue development
of vintafolide.
Endocyte will evaluate vintafolide for future development opportunities
pending final results from the Phase 2b TARGET trial in patients with non-
small cell lung cancer (NSCLC). The companies announced in March that the
TARGET trial met its primary progression-free-survival (PFS) endpoint and
overall response rates and early overall survival (OS) trends were positive.
Neither company has received updated overall survival data since that
announcement.
"We look forward to presenting detailed data from the ongoing Phase 2b
TARGET trial at an upcoming scientific conference later this year, which
will inform the path forward for vintafolide," said Ron Ellis, Endocyte's
president and chief executive officer. "We remain confident in our SMDC
platform and are in a strong financial position to continue to advance two
proprietary SMDCs with the more potent tubulysin warhead. Tubulysin has
demonstrated curative activity in preclinical models that were resistant to
paclitaxel, cisplatin and vintafolide. These two SMDCs are currently in
Phase 1 development: EC1456, targeting the folate receptor, and EC1169,
targeting prostate-specific membrane antigen (PSMA)."
